SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells 8,500 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 8,500 shares of the firm’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $5.62, for a total transaction of $47,770.00. Following the sale, the chairman owned 3,532,622 shares of the company’s stock, valued at approximately $19,853,335.64. This represents a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total transaction of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.25, for a total transaction of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total transaction of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.80, for a total transaction of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total transaction of $44,540.00.
• On Monday, April 20th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.21, for a total transaction of $23,372.06.
• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.00, for a total value of $87,365.00.

SOPHiA GENETICS Stock Down 0.7%

SOPH traded down $0.04 during trading on Tuesday, reaching $5.68. 120,863 shares of the stock traded hands, compared to its average volume of 190,422. The stock has a market cap of $476.50 million, a price-to-earnings ratio of -10.92 and a beta of 0.96. SOPHiA GENETICS SA has a fifty-two week low of $2.92 and a fifty-two week high of $6.30. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The stock’s 50-day simple moving average is $5.18 and its two-hundred day simple moving average is $4.99.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The firm had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million.

Analyst Upgrades and Downgrades

A number of research firms recently commented on SOPH. BTIG Research restated a “buy” rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $7.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after acquiring an additional 5,432,871 shares during the period. Akre Capital Management LLC lifted its position in SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after acquiring an additional 1,481,636 shares during the last quarter. Hodges Capital Management Inc. bought a new stake in SOPHiA GENETICS during the first quarter valued at about $2,157,000. Royce & Associates LP bought a new stake in SOPHiA GENETICS during the fourth quarter valued at about $2,009,000. Finally, Sei Investments Co. acquired a new stake in shares of SOPHiA GENETICS in the first quarter valued at about $1,772,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.